Medical Isotope Shortage Predicted to Cause Fatalities in the UK

Experts are issuing a grave warning that a scarcity of specialized medicine, crucial for detecting conditions like breast and bowel cancer, will result in fatalities. They state that the insufficient availability of medical radioactive isotopes in the UK is leading to delays in cancer diagnostic tests. This situation has intensified calls for the UK to establish its own manufacturing capabilities for nuclear medicines, rather than depending on foreign imports. This development follows a proposal for a new £400 million medical laboratory intended for a former nuclear plant site in north Wales. The initiative, named Project Arthur, envisions installing a small-scale nuclear reactor at Trawsfynydd in Gwynedd to produce these vital radioactive materials. The nuclear-based medicine serves to identify cancer tumours in patients and monitor disease progression. However, the UK has received no new supplies after a reactor in the Netherlands was compelled to cease production for the entirety of the previous month. Prof Simon Middleburgh, from Bangor University’s Nuclear Futures Institute, emphasized the severity of the situation: “For every month that we don’t have diagnosis, or a person doesn’t have a diagnosis, their chances of succumbing to cancer increase by 10 per cent.” He added, “It is actually resulting in people dying from this now.” Prof Middleburgh further elaborated, “These people are not getting the diagnosis, they are not getting those cancers caught early on, cancer will spread, people will die.” He concluded, “It’s going to be hundreds if not thousands due to just this month’s shortage in isotopes this time around.” Prof Middleburgh explained his support for Project Arthur, which the Welsh government initially presented in January 2023. A feasibility study for the project was commissioned, and a business case is now being submitted to the UK government, seeking funding approval for the scheme. This would establish a domestic supply of nuclear isotopes for the whole of Britain. “The business case is there, it’s not new technology, it’s old technology – we can buy it of the shelf,” Prof Middleburgh stated. He continued, “It’s not just a Wales thing – it’s an across the UK thing – we’re all ready to go, it is just time to press the green button and get on with it.” Radioisotopes are utilized for diagnosing cancer and treating specific types, such as prostate and liver cancer, by being injected or swallowed and subsequently absorbed by cancerous cells within the body. Their use is a very common method for both treating and diagnosing patients within the NHS. Typically, individuals receive a dose of this nuclear medicine, which is introduced into their body and emits radiation. Gamma radiation, for instance, is a type of radiation. As it exits the body, it can be detected by a scanner to reveal the cancer’s size and location. This process should not be confused with external radiotherapy, which involves directing radiation at tumours from outside the body. It is estimated that a facility, if approved immediately, would not become operational until approximately 2030. In the interim, the UK government’s Department of Health and Social Care has stated its efforts to tackle the current scarcity of nuclear isotopes. A UK government official commented, “We know this may be concerning for patients and we are working closely with the company involved to resolve the issue.” The official added, “We are also working in close partnership with NHS England and the devolved governments to distribute available stock and prioritise patients with critical needs.” The Welsh government affirmed its continued backing for the Trawsfynydd proposals, indicating its collaboration with all partners to advance the plans. They stated, “We will provide an update on progress in due course.” However, Liz Saville-Roberts, the Plaid Cymru MP for the area, stressed the need for prompt action to prevent a recurrence of the current isotope shortage. “Welsh government need to be pushing the business case as hard as possible. They need to have it costed, they need to work with Bangor University who will be alongside this, and the UK government has got to recognise – yes – this will cost, but look at the cost if we don’t,” said Saville-Roberts. She concluded, “We are going to be talking about a cost in life.”